Blood Market by Product (Whole Blood Collection and Processing, Source Plasma Collection, Blood Typing Products, and Blood Screening Products) and End User (Blood & Blood Component Bank, Diagnostic Laboratories, Ambulatory Surgical Centers, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL3931809
- 261 Pages
- May 2020
- Medical Devices
Blood is vital for life and is required for normal functioning of the human body. Furthermore, bone marrow is responsible for the production of blood cells in the body. However, various medical conditions can lead to altered level of blood, which can be fatal for a patient. For instance, medical conditions such as chronic kidney diseases, cancer, and hemophilia B require blood transfusions for treatment. Moreover, in event of a trauma, which causes injury to a patient, blood transfusion is might be required for treatment based on the nature of the injury. Similarly, surgeries can also lead to major blood loss leading to the need for blood transfusions. Furthermore, plasma is a major content of blood and low level of plasma in the body can hamper normal functioning. Thus, patients who suffer from medical conditions such as liver diseases lead to lower plasma level requiring plasma transfusions. Thus, collection of blood is a necessary task and requires the use of reagents and blood collection systems. Moreover, the collected blood is subjected to screening, which further requires use of systems and reagents. This collected and screened blood is then circulated to various end users such as blood and blood component banks, diagnostic laboratories, ambulatory surgical centers, and hospitals.
Growth of the blood market is driven by factors such as surge in demand for blood and plasma across the globe and rise in geriatric population worldwide. In addition, increase in blood and plasma donations across the globe and favorable government regulations for blood screening are some other factors that boost the growth of the market.
Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives growth of the blood market. However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Conversely, developing economies offer lucrative growth opportunities for the market growth.
The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. Furthermore, all these segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. In addition, the blood typing products are further bifurcated into blood typing systems, blood typing reagents. The blood screening products are divided into blood screening systems, and blood screening reagents.
On the basis of end user, the market is divided into blood and blood component bank, diagnostic laboratories, ambulatory surgical centers, hospitals, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., CSL Limited (CSL Behring), F. Hoffmann-La Roche Ltd., Grifols International SA, Haemonetics Corporation, Merck & Co., Inc., Novo Nordisk A/S, Ortho Clinical Diagnostics, and Terumo Corporation (Terumo BCT, Inc.) are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global blood market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Product
o Whole Blood Collection and Processing
§ Whole Blood Collection Systems
§ Whole Blood Collection Consumables
o Source Plasma Collection
§ Source Plasma Collection Systems
§ Source Plasma Collection Consumables
o Blood Typing Products
§ Blood Typing Systems
§ Blood Typing Reagents
o Blood Screening Products
§ Blood Screening Systems
§ Blood Screening Reagents
• By End User
o Blood & Blood Component Bank
o Diagnostic Laboratories
o Ambulatory Surgical Centers
o Blood And Blood Component Bank
o Others
• By Region
o North America
§ U.S.
§ Canada
§ Mexico
o Europe
§ Germany
§ France
§ UK
§ Italy
§ Rest of Europe
o Asia-Pacific
§ Japan
§ China
§ India
§ Rest of Asia-Pacific
o LAMEA
§ Brazil
§ Saudi Arabia
§ South Africa
§ Rest of LAMEA
• List of key players profiled in the report:
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• CSL Limited (CSL Behring).
• F. Hoffmann-La Roche Ltd.
• Grifols International SA
• Haemonetics Corporation
• Merck & Co., Inc.
• Novo Nordisk A/S
• Ortho Clinical Diagnostics
• Terumo Corporation (Terumo BCT, Inc.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Fresenius Kabi
• Qiagen N.V.
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.3.Key forces shaping blood industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in demand for blood and other blood related products across the globe
3.4.1.2.Rise in geriatric population across the globe
3.4.1.3.Surge in blood donations and plasma donations across the globe
3.4.1.4.Favorable government regulations for blood screening
3.4.1.5.Advancements in blood transfusion and blood screening instruments
3.4.2.Restraints
3.4.2.1.High cost of advanced blood collection devices
3.4.2.2.Lack of skilled laboratory professionals
3.4.3.Opportunities
3.4.3.1.Developing economies offer lucrative growth opportunities
3.4.4.Impact Analysis
3.5.Blood Therapeutics
3.5.1.Key market trends, growth factors, and opportunities
3.5.2.Market size and forecast, by product
3.5.2.1.Intravenous Immunoglobulin
3.5.2.1.1.Market size and forecast
3.5.2.2.Factor IX
3.5.2.2.1.Market size and forecast
3.5.2.3.Factor VIII
3.5.2.3.1.Market size and forecast
3.5.2.4.Albumin
3.5.2.4.1.Market size and forecast
3.5.2.5.Hyperimmune
3.5.2.5.1.Market size and forecast
3.5.2.6.Others
3.5.2.6.1.Market size and forecast
3.5.3.Market size and forecast, by region
CHAPTER 4:BLOOD MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Whole blood collection and processing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Whole Blood Collection and Processing Systems
4.2.2.1.1.Market size and forecast
4.2.2.1.2.Market size and forecast, by region
4.2.2.2.Whole Blood Collection and Processing Consumables
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Source plasma collection
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Source Plasma Collection Systems
4.3.2.1.1.Market size and forecast
4.3.2.1.2.Market size and forecast, by region
4.3.2.2.Source Plasma Collection Consumables
4.3.2.2.1.Market size and forecast
4.3.2.2.2.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Blood typing products
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Blood Typing Systems
4.4.2.1.1.Market size and forecast
4.4.2.1.2.Market size and forecast, by region
4.4.2.2.Blood Typing Reagents
4.4.2.2.1.Market size and forecast
4.4.2.2.2.Market size and forecast, by region
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Blood screening products
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Blood Screening Systems
4.5.2.1.1.Market size and forecast
4.5.2.1.2.Market size and forecast, by region
4.5.2.2.Blood Screening Reagents
4.5.2.2.1.Market size and forecast
4.5.2.2.2.Market size and forecast, by region
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:BLOOD MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Blood and blood component bank
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Diagnostic laboratories
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ambulatory surgical centers
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Hospitals
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:BLOOD MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. blood market size and forecast, by product
6.2.2.1.2.U.S. blood market size and forecast, by end user
6.2.2.2.Canada
6.2.2.2.1.Canada blood market size and forecast, by product
6.2.2.2.2.Canada blood market size and forecast, by end user
6.2.2.3.Mexico
6.2.2.3.1.Mexico blood market size and forecast, by product
6.2.2.3.2.Mexico blood market size and forecast, by end use
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by end user
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany blood market size and forecast, by product
6.3.2.1.2.Germany blood market size and forecast, by end user
6.3.2.2.France
6.3.2.2.1.France blood market size and forecast, by product
6.3.2.2.2.France blood market size and forecast, by end user
6.3.2.3.UK
6.3.2.3.1.UK blood market size and forecast, by product
6.3.2.3.2.UK blood market size and forecast, by end user
6.3.2.4.Italy
6.3.2.4.1.Italy blood market size and forecast, by product
6.3.2.4.2.Italy blood market size and forecast, by end user
6.3.2.5.Spain
6.3.2.5.1.Spain blood market size and forecast, by product
6.3.2.5.2.Spain blood market size and forecast, by end user
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe blood market size and forecast, by product
6.3.2.6.2.Rest of Europe blood market size and forecast, by end user
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by end user
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan blood market size and forecast, by product
6.4.2.1.2.Japan blood market size and forecast, by end user
6.4.2.2.China
6.4.2.2.1.China blood market size and forecast, by product
6.4.2.2.2.China blood market size and forecast, by end user
6.4.2.3.Australia
6.4.2.3.1.Australia blood market size and forecast, by product
6.4.2.3.2.Australia blood market size and forecast, by end user
6.4.2.4.India
6.4.2.4.1.India blood market size and forecast, by product
6.4.2.4.2.India blood market size and forecast, by end user
6.4.2.5.South Korea
6.4.2.5.1.South Korea blood market size and forecast, by product
6.4.2.5.2.South Korea blood market size and forecast, by end user
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific blood market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific blood market size and forecast, by end user
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by end user
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil blood market size and forecast, by product
6.5.2.1.2.Brazil blood market size and forecast, by end user
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia blood market size and forecast, by product
6.5.2.2.2.Saudi Arabia blood market size and forecast, by end user
6.5.2.3.South Africa
6.5.2.3.1.South Africa blood market size and forecast, by product
6.5.2.3.2.South Africa blood market size and forecast, by end user
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA blood market size and forecast, by product
6.5.2.4.2.Rest of LAMEA blood market size and forecast, by end user
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.1.2.1. Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BIO-RAD LABORATORIES, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CSL LIMITED (CSL BEHRING)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.F. HOFFMANN-LA ROCHE LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS INTERNATIONAL SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.HAEMONETICS CORPORATION
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MERCK & CO., INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.NOVO NORDISK A/S
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.ORTHO CLINICAL DIAGNOSTICS
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments
7.10.TERUMO CORPORATION (TERUMO BCT, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
TABLE 01.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY TYPE 2019–2027 ($MILLION)
TABLE 02.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY REGION 2019–2027 ($MILLION)
TABLE 03.GLOBAL BLOOD MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY TYPE 2019–2027 ($MILLION)
TABLE 05.WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 06.WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 07.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 08.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY TYPE 2019–2027 ($MILLION)
TABLE 09.SOURCE PLASMA COLLECTION SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 10.PLASMA COLLECTION CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 11.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 13.BLOOD TYPING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 14.BLOOD TYPING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 15.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 16.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 17.BLOOD SCREENING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 18.BLOOD SCREENING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 19.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GLOBAL BLOOD MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 21.BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY REGION 2019–2027($MILLION)
TABLE 22.BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION 2019–2027($MILLION)
TABLE 23.BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION 2019–2027($MILLION)
TABLE 24.BLOOD MARKET FOR HOSPITALS, BY REGION 2019–2027($MILLION)
TABLE 25.BLOOD MARKET FOR OTHERS , BY REGION 2019–2027($MILLION)
TABLE 26.BLOOD MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 27.SCREENING OF DONATED BLOOD IN U.S.
TABLE 28.NORTH AMERICA BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 29.U.S. BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 30.U.S. BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 31.CANADA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 32.CANADA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 33.MEXICO BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 34.MEXICO BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 35.NORTH AMERICA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 36.NORTH AMERICA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 37.EUROPE BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 38.GERMANY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 39.GERMANY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 40.FRANCE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 41.FRANCE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 42.UK BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 43.UK BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 44.ITALY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 45.ITALY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 46.SPAIN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 47.SPAIN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 48.REST OF EUROPE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 49.REST OF EUROPE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 50.EUROPE BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 51.EUROPE BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 52.ASIA-PACIFIC BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 53.JAPAN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 54.JAPAN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 55.CHINA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 56.CHINA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 57.AUSTRALIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 58.AUSTRALIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 59.INDIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 60.INDIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 61.SOUTH KOREA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 62.SOUTH KOREA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 66.ASIA-PACIFIC BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 67.MIDDLE EAST BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 68.BRAZIL BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 69.BRAZIL BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 70.SAUDI ARABIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 71.SAUDI ARABIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 72.SOUTH AFRICA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 73.SOUTH AFRICA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 74.REST OF LAMEA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 75.REST OF LAMEA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 76.LAMEA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 77.LAMEA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 78.ABBOTT: COMPANY SNAPSHOT
TABLE 79.ABBOTT: OERATING SEGMENT
TABLE 80.ABBOTT: PRODUCT PORTFOLIO
TABLE 81.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82.BIO-RAD: COMPANY SNAPSHOT
TABLE 83.BIO-RAD: OERATING SEGMENT
TABLE 84.BIO-RAD: PRODUCT PORTFOLIO
TABLE 85.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86.CSL: COMPANY SNAPSHOT
TABLE 87.CSL: OERATING SEGMENT
TABLE 88.CSL: PRODUCT PORTFOLIO
TABLE 89.ROCHE: COMPANY SNAPSHOT
TABLE 90.ROCHE: OERATING SEGMENT
TABLE 91.ROCHE: PRODUCT PORTFOLIO
TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.GRIFOLS: COMPANY SNAPSHOT
TABLE 94.GRIFOLS: OERATING SEGMENT
TABLE 95.GRIFOLS: PRODUCT PORTFOLIO
TABLE 96.GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.HAEMONETICS: COMPANY SNAPSHOT
TABLE 98.HAEMONETICS: OPERATING SEGMENTS
TABLE 99.HAEMONETICS: PRODUCT PORTFOLIO
TABLE 100.HAEMONETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.MERCK: COMPANY SNAPSHOT
TABLE 102.MERCK: OPERATING SEGMENTS
TABLE 103.MERCK PRODUCT PORTFOLIO
TABLE 104.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 105.NOVO NORDISK: OERATING SEGMENT
TABLE 106.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 107.NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108.ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 109.ORTHO CLINICAL DIAGNOSTICS.: PRODUCT PORTFOLIO
TABLE 110.ORTHO CLINICAL DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.TERUMO: COMPANY SNAPSHOT
TABLE 112.TERUMO: OERATING SEGMENT
TABLE 113.TERUMO: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
